Dr. Jonah Essers, a pediatric gastroenterologist in Seattle, reversed a Cigna Healthcare denial for a 17-year-old patient’s Skyrizi infusion by publicly tagging the insurer and its chief medical officer on LinkedIn — and his posts, repeated across a dozen or so cases, almost always ended in approval, HEALTH CARE un-covered reported.
Two days later, after a Cigna physician missed a promised peer-to-peer call, he posted a video pressing the same complaint. In September, the insurer overturned the denial in a phone call, conceding the claim had been mishandled by a per-diem doctor who lacked the proper experience.
Why it matters: Essers’s workaround targets a system that most physicians cannot beat with paperwork alone. An insurer that reversed a denial only after public pressure, its own admitting a mishandled review, shows how far the standard appeal process sits from what clinicians consider medically sound.
How to Speed up a Prior-Authorization Appeal
- Prior authorization means your insurer must approve a treatment before you get it. An initial denial is not final — but standard appeals take time your doctor may not have.
- Delays are not harmless. In patient surveys, roughly a quarter of Americans who faced a prior-authorization denial said they got sicker as a result.
- Ask your doctor whether an appeal has been filed, and ask for the insurer’s executive or peer-to-peer review channel — the routes Essers found work better than the standard fax queue.
The Numbers Behind the Denials
Five years ago, the American Medical Association surveyed just over 1,000 physicians about prior authorization. Of those surveyed, 93% said the hassles can cause patients to delay treatment, 82% said they could lead patients to abandon needed care, 24% said denials led to hospitalizations, and 8% said denials had caused patient disabilities or even deaths.
A recent Commonwealth Fund survey found that more than one in five Americans experienced a claim denial for themselves or a family member. Among patients denied through prior authorization, 41% said it delayed their care and 28% said they became sicker as a result.
| Measure | Source | Figure |
|---|---|---|
| Physicians saying prior authorization causes treatment delays | AMA survey of 1,000+ physicians | 93% |
| Physicians saying it can lead patients to abandon care | AMA survey | 82% |
| Physicians saying denials led to hospitalizations | AMA survey | 24% |
| Patients with prior-auth denial who said they became sicker | Commonwealth Fund survey | 28% |
Why Insurers Keep the Gate
Kevin Schulman, a professor of medicine at Stanford University who studies health economics and prior authorization, said many claims founder in a system still largely analog — paperwork and fax machines in a digital world.
Most procedures or drug regimens are eventually approved, he noted, but often only after time-wasting appeals. “At the end of the day, you have to go back and ask the question, ‘why?’” he said in a phone interview.
The financial logic is clear. Rejecting claims or steering patients toward lower-cost but often less effective medicines reduces insurers’ expenses by an estimated 5-7% — across the industry, as much as $40 billion in additional revenue every year, HEALTH CARE un-covered reported.
Artificial intelligence is entering the gate as well. Essers sees a double edge: he now uses AI himself to assemble the medical articles and draft the appeal letters he faxes to insurers.
What the Squeaky Wheel Actually Won
The Skyrizi case is not isolated. Essers has appealed to executives not just at Cigna but at Aetna and Premera Blue Cross, the largest health insurance provider in the Pacific Northwest, in nearly a dozen cases — with almost always positive outcomes for his patients, he said in a phone interview.
He believes his repeated pressure on Premera played a role in the insurer creating a medical-director call line, where he can book time with one of its physicians, usually with a positive result. “And that was sort of based on essentially just hammering them,” he said.
They don’t tell you about it,” he said.
The pressure has drawn institutional attention. A couple of years ago, when Essers was based at a prominent Seattle hospital, top Aetna officials complained to the hospital’s administration.
“The CMO essentially called me in and was like, ‘What’s going on here? We’re getting complaints that you’re, you know, harassing Aetna,’” he recounted. “And I showed her all the posts, and she’s like, ‘This is brilliant. You know, you’re doing God’s work.’”
From LinkedIn Posts to Legislation
Essers and Dr. Brad Pasternak, a fellow pediatric gastroenterologist in Phoenix who also chronicles denials on LinkedIn, are writing an academic paper on why these tactics work — Essers is also working with a physician in Arizona on the project. Pasternak’s own post this summer, about a 6-year-old patient denied approval for an anti-inflammatory drug she had taken previously, read: “A child is waiting. Disease unchecked.”
Essers said he thinks it will ultimately require legislation. Angry LinkedIn posts may be effective, but they are not the long-term solution.
Do Not Wait If Symptoms Worsen During Delay
This story is about insurance process, not a treatment decision — but the clinical stakes are real. If a prescribed biologic or infusion therapy such as Skyrizi is delayed by a denial, do not simply wait: contact your prescribing physician, who can file a formal appeal or request a peer-to-peer review with the insurer’s medical director.
Patients who experience worsening symptoms while a medication is held — for inflammatory bowel disease, that can mean bleeding, fever, or severe abdominal pain — should seek medical care promptly rather than waiting on the appeal. Any change in an approved treatment regimen, including switching biologics, requires physician supervision; never stop or substitute a therapy on your own.
What Remains Unresolved
Cigna’s own concession — that a per-diem doctor without the proper experience mishandled the 17-year-old’s claim — has not been followed by any public accounting of how such reviews are staffed.
References
- American Medical Association physician survey on prior authorization (1,000+ physicians)
- Commonwealth Fund survey on insurance claim denials
- Kevin Schulman, Stanford University School of Medicine, health economics research on prior authorization
- National Association of Insurance Commissioners, 2024 insurer AI survey
Disclaimer: This article is journalistic coverage and does not constitute medical advice. Readers should consult their own physicians regarding any treatment decision.